Kisspeptin-10: the molecule named after a chocolate bar.

The naming is genuinely the strangest part. In 1996 a group at the Penn State College of Medicine in Hershey, Pennsylvania, cloned a gene that suppressed metastasis when re-expressed in melanoma cells. They needed a symbol. They picked KISS1 — a wink to Hershey's most famous export. When the gene's peptide product turned out, seven years later, to be the master regulator of mammalian reproduction, the name stuck. An entire branch of endocrinology now traces its terminology to a foil-wrapped chocolate.

From metastasis suppressor to reproductive master switch

The functional pivot happened in 2003. Two groups — one in France led by Catherine Dodé, one in the United States — independently identified loss-of-function mutations in GPR54, the receptor for kisspeptin, in patients with idiopathic hypogonadotropic hypogonadism. The implication was immediate: kisspeptin signaling, acting upstream of GnRH (gonadotropin-releasing hormone), was the gate that opened the reproductive system at the start of puberty.

Confirming experiments came fast. Administer kisspeptin to a healthy adult and gonadotropin secretion rises within minutes. Administer it to a prepubertal animal and the entire pubertal cascade can be initiated. Block kisspeptin signaling and the cascade fails.

Mechanism, in plain language

Kisspeptin neurons live in two main hypothalamic populations: the anteroventral periventricular nucleus and the arcuate nucleus. Both project to GnRH neurons. When kisspeptin neurons fire, they release the peptide onto GnRH neurons, which respond by firing and releasing GnRH into the hypothalamic-pituitary portal blood. GnRH then triggers the pituitary to release LH and FSH, which act on the gonads to drive testosterone, estradiol, and gametogenesis.

Kisspeptin sits one node upstream of the system everyone has been measuring for half a century. A patient whose GnRH neurons are intact but whose endogenous kisspeptin signaling is blunted — by stress, undernutrition, or hypothalamic disorder — can sometimes have the entire downstream cascade restored by exogenous kisspeptin, while leaving the patient's own regulatory feedback loops intact.

The 2025 picture

The most consequential recent paper is from the Dhillo and Abbara group at Imperial College London, published in eBioMedicine in 2025. The team tested intranasal kisspeptin-54 in healthy men, healthy women, and patients with hypothalamic amenorrhoea. The intranasal route bypassed the need for IV infusion. Gonadotropin release was robust and rapid in all three groups, with no observed adverse events.

An intranasal route turns kisspeptin from a research-grade infusion into something that could plausibly be a clinical agent.

Beyond the obvious

The metabolic literature is where kisspeptin gets quietly interesting. KISS1R is expressed in the pancreas, white and brown adipose tissue, and the liver. A 2018 human study by Izzi-Engbeaya and colleagues showed that kisspeptin enhanced glucose-stimulated insulin secretion in vivo without affecting insulin sensitivity. Mouse work from the Tolson group at UC San Diego showed that loss of kisspeptin signaling produced obesity, glucose intolerance, and reduced energy expenditure independent of the reproductive defects.

Adjacent research

In studies probing the hypothalamic-pituitary-gonadal axis, kisspeptin-10 is often paired with HCG. The two act on different layers of the same system: kisspeptin upstream at the hypothalamus, HCG downstream as an LH-mimetic at the gonads. Researchers using both compounds in the same protocol can dissect which layer of the axis is responsive in a given patient or model.

Practical considerations

Kisspeptin-10 is supplied as a lyophilized powder. Plasma half-life of the 10-residue form is short — minutes — which is why most clinical protocols have used continuous infusion or repeated subcutaneous dosing.